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The epidemic of Ebola virus disease (EVD) in West Africa in 2014-2016 was the largest and most 8 
complicated the world has ever seen. The four pillars of Ebola response include: case management; 9 
case finding and contact tracing; safe and dignified burial; and social mobilisation and community 10 
engagement. These are being implemented in the current outbreak in the Democratic Republic of 11 
Congo (DRC), that is further complicated by its location in a conflict zone1.  Increased understanding 12 
of disease pathogenesis and the evaluation of novel therapeutics and vaccine candidates has 13 
informed current control measures, whilst access to survivors and their contacts in West Africa also 14 
provides a unique opportunity to research Filovirus transmission.  15 
In their article published in The Lancet Infectious Diseases, Diallo and colleagues (ref) report data 16 
from a large cross-sectional study of contacts of an established survivor cohort in Guinea. They 17 
aimed to estimate the frequency of unrecognised Ebola virus infection (EVI) in contacts, after 18 
excluding those that were vaccinated, and to identify risk factors for infection. Utilising a novel and 19 
previously validated Luminex assay 2 on dried blood spots, and detailed retrospective exposure 20 
histories they identified 57 EVIs among 1390 contacts (4.1%).  21 
They demonstrated increased seropositivity in contacts who reported any symptom associated with 22 
EVD (8·33%; 95% CI: 5·01% to 12·80%, described as paucisymptomatic contacts) compared to EVI in 23 
asymptomatic contacts (3.32%; 95% CI: 2·37% to 4·51%, p=0.0002). Participation in burial rituals and 24 
contact with blood or vomit were independent significant risk factors for EVI in asymptomatic 25 
contacts in multivariate analysis, whilst older age and participation in burial practices were risk 26 
factors in paucisymptomatic cases. Their findings concur with a recent meta-analysis of 27 
seroprevalence surveys 3 and the results of a study in Sierra Leone of 486 household members of 28 
EVD survivors, which identified EVI in 12% (95% CI: 6·1–20·4) of those with symptoms compared to  29 
2·6% (95% CI: 1·2–4·8) of asymptomatic household members4. The same study also demonstrated 30 
that burial contact and older age were risk factors for EVI5.  31 
The conclusions drawn by Diallo et al reaffirm the challenges/failures in case finding and contact 32 
tracing highlighted by others in Guinea6. This is evidenced by the 73% of paucisymptomatic contacts 33 
who, in reporting a history of fever,  met the WHO definitions for suspect cases that required 34 
isolation and further evaluation7,8. Furthermore, they highlight that 30/216 paucisymptomatic 35 
contacts met the EVD suspect case definition without contact but were not diagnosed acutely, of 36 
whom 20% were seropositive. These results are timely as in the DRC, as of 23 October, 5723 37 
contacts remain under surveillance, with follow-up rates ranging from 85-97% 9.  The data from 38 
Diallo et al highlights the varying spectrum of EVD severity, consistent with early clinical reports in 39 
West Africa10, and again challenges our perceptions of the roles and balance of viral infective dose 40 
and host immune response in clinical phenotypes. Studies like this may be unique, and impossible to 41 
replicate, because of the scale of the West African outbreak and the now-established practice of ring 42 
vaccination. 43 
Care must also be taken in the interpretation and extrapolation of these results. As the authors 44 
acknowledge, there is risk of recall bias: it is challenging to remember clinical symptoms, exposure 45 
and exact timing over two years after the event. The key ‘question’ is whether these unidentified EVI 46 
contacts had any role in transmission chains. This issue was recently highlighted by Dokubo et al 11, 47 
who reported a familial cluster occurring in Liberia one year after an undiagnosed EVI in a female 48 
contact, due to viral persistence.  This potential transmission risk must be balanced against the risk 49 
of further stigmatisation of both survivors and household contacts.  50 
This study reinforces the importance of robust and detailed contact tracing as a control measure and 51 
highlights the high risk posed by burial practices and direct contact with infected fluids. What is also 52 
notable is how few contacts (>90%) who reported high-risk exposures were infected.  Greater 53 
understanding is needed about the mechanisms of Ebola virus transmission in order to improve the 54 
targeting of interventions as part of a coordinated response. Epidemics of Ebola virus disease remain 55 
a major risk to healthcare workers and populations in endemic regions, as well as a global threat to 56 
health security.  57 
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